Key result
Rivaroxaban plus low-dose aspirin reduces MACE in stable CAD.
Why the study?
Patients with established CV disease often suffer recurrent events despite optimal therapy, prompting a review of the COMPASS study results and their impact on everyday clinical practice.
Does rivaroxaban 2.5 mg twice daily given with low-dose aspirin reduce the incidence of the composite endpoint of stroke, heart attack, and death in patients with stable coronary artery disease?
Does rivaroxaban 2.5 mg twice daily given with low-dose aspirin reduce the incidence of the composite endpoint of stroke, heart attack, and death in patients with stable coronary artery disease?
Rivaroxaban 2.5 mg twice daily combined with low-dose aspirin reduces major cardiovascular events in patients with stable coronary artery disease, potentially changing secondary prevention strategies.
Low-certainty evidence supports rivaroxaban plus aspirin in stable CAD; leaves open need for confirmatory trials before practice change.
Patients with established cardiovascular (CV) disease may suffer further CV events, despite receiving optimal medical treatment. Although platelet inhibition plays a central role in the prevention of new events, the use of anticoagulant therapies to reduce events in atheromatous disease has, until recently, been overlooked. The recent Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS) trial showed that rivaroxaban 2.5 mg twice daily given with low-dose aspirin reduces the incidence of the composite endpoint of stroke, heart attack, and death in patients with stable coronary artery disease. Although there are some limitations to the study, COMPASS offers promising conclusions and may change secondary prevention in patients with stable CV disease. This article reviews the results of the COMPASS study and how these results may affect patient management in everyday clinical practice.
No takes yet. Share an insight, caveat, or question.
Bolognese et al. (2020) conducted a review in stable coronary artery disease. rivaroxaban with low-dose aspirin was evaluated on composite endpoint of stroke, heart attack, and death. Rivaroxaban 2.5 mg twice daily with low-dose aspirin reduces the incidence of stroke, heart attack, and death in patients with stable coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: